Reaction
Dental Care reporting signals
As of the last recalculation, Dental Care appears in 1,826 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is DENOSUMAB (PRR 45.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Denosumab | 566 | 45.7 | 45.8 |
| Romosozumab-Aqqg | 25 | 21.3 | 21.3 |
| Cyclobenzaprine Hydrochloride | 7 | 8.9 | 8.9 |
| Avapritinib | 9 | 8.5 | 8.5 |
| Sodium Oxybate | 48 | 8.5 | 8.5 |
| Ibrutinib | 57 | 8.3 | 8.3 |
| Vibegron | 5 | 7.1 | 7.1 |
| Armodafinil | 13 | 7.1 | 7.1 |
| Niraparib | 13 | 6.7 | 6.7 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate | 19 | 6.2 | 6.2 |
| Axitinib | 9 | 5.3 | 5.3 |
| Naltrexone | 14 | 5.2 | 5.2 |
| Apalutamide | 4 | 3.9 | 3.9 |
| Emicizumab | 4 | 3.7 | 3.7 |
| Relugolix | 7 | 3.4 | 3.4 |
| Palbociclib | 27 | 3.3 | 3.3 |
| Certolizumab Pegol | 33 | 3.3 | 3.3 |
| Bimekizumab | 6 | 3.2 | 3.2 |
| Lifitegrast | 3 | 2.1 | 2.1 |
| Guselkumab | 5 | 1.6 | 1.6 |
| Valbenazine | 3 | 1.4 | 1.4 |